Primary hyperaldosteronism medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 77: | Line 77: | ||
|Calcium channel blockers | |Calcium channel blockers | ||
| | | | ||
* Amlodipine | |||
* Nifedipine | |||
| | | | ||
* Prevent '''calcium''' from entering cells of the | * Prevent '''calcium''' from entering cells of the blood vessel walls, resulting in lower blood pressure<ref name="pmid3540226">{{cite journal |vauthors=Katz AM |title=Pharmacology and mechanisms of action of calcium-channel blockers |journal=J Clin Hypertens |volume=2 |issue=3 Suppl |pages=28S–37S |year=1986 |pmid=3540226 |doi= |url= |issn=}}</ref> | ||
| | | | ||
* 5 mg OD | |||
* Max of 10 mg OD<ref name="urlwww.accessdata.fda.gov2">{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019787s042lbl.pdf |title=www.accessdata.fda.gov |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
| | | | ||
* Edema | |||
* Flushing | |||
* Diziness | |||
* Palpitations | |||
* Headache | |||
* Abdominal pain | |||
* Somnolence<ref name="urlwww.accessdata.fda.gov3">{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019787s042lbl.pdf |title=www.accessdata.fda.gov |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
|- | |- | ||
|ACE inhibitors | |ACE inhibitors | ||
Revision as of 17:10, 10 July 2017
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism medical therapy On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism medical therapy |
|
Risk calculators and risk factors for Primary hyperaldosteronism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The optimal therapy for primary hyperladosteronism depends on the etiology of hyperaldosteronism.
Medical Therapy
Medical therapy is indicated for bilateral adrenal hyperplasia and all ambiguous causes of primary hyperaldosteronism. The following agents may be used to medical management of primary hyperaldosteronism:
| Drug Class | Agents | Mechanism of action | Dosage | Side effects |
|---|---|---|---|---|
| Mineralocorticoid receptor antagonists | Spironolactone |
|
|
|
| Potassium canrenoate |
|
|||
| Eplerenone |
|
50 mg OD[2] |
| |
| Potassium-sparing diuretics |
|
|
|
|
| Calcium channel blockers |
|
|
|
|
| ACE inhibitors | ||||
| Angiotensin receptor blockers | ||||
| Dexamethasone therapy(For familial hyperaldosteronism type I) |
|
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ Craft J (2004). "Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure". Proc (Bayl Univ Med Cent). 17 (2): 217–20. PMC 1200656. PMID 16200104.
- ↑ Vidt DG (1981). "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic". Pharmacotherapy. 1 (3): 179–87. PMID 6927605.
- ↑ "Amiloride Dosage Guide with Precautions - Drugs.com".
- ↑ Katz AM (1986). "Pharmacology and mechanisms of action of calcium-channel blockers". J Clin Hypertens. 2 (3 Suppl): 28S–37S. PMID 3540226.
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ "www.accessdata.fda.gov" (PDF).